Treeway logo

Treeway

Accelerating ALS (Amyotrophic Lateral Sclerosis) therapy development. One man can and will find a way, why not be that man... Treeway B.V., is a biotech company, focus on the rational target validation and drug development therapies for the treatment and cure of Amyotrophic lateral sclerosis (ALS).

Treeway has been founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS. Treeways strategy is founded on a cohesive combination of approaches that together should provide the highest likelihood of bringing successful treatments for ALS to the patient in the short term. Founders have also initiated Project MinE that aims to discover the genes that are associated with ALS to find the gentic causes.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://treeway.nl
Founded2012
Disease Focus
Development Stage
STOCK CODENon Listed
Address
Maidstone 48a 5026 SK
Rotterdam
Netherlands
Email
info@treeway.nl
Contact Number
+31 88 8733 929

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/treeway” connections=”true” suffix=””]

In Jan 2015, uniQure granted Treeway B.V., an exclusive license to IP covering adeno-associated virus serotype 5 (AAV5)-based gene therapy vector and glial cell-derived neurotrophic factor (GDNF) in ALS. Under the terms Treeway and uniQure will jointly commercialize any resulting ALS gene therapy with defined geographical rights for commercialization assigned to each company. Financial details of the agreement were not disclosed.